NEW YORK (GenomeWeb News) – Molecular diagnostics firm IntegraGen said today that it has acquired the exclusive rights to use a specific microRNA as a biomarker for predicting patient outcomes in metastatic colorectal cancer.

The license was obtained from the Paris Descartes University, INSERM, the Centre National de la Recherche Scientifique, and the Assistance Publique — Hopitaux de Paris. Terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: spatiotemporal study of lncRNA expression, role of extrachromosomal, circular DNAs in yeast, and more.

A European team has launched a four-year study to develop a test to gauge cervical, ovarian, uterine, or aggressive breast cancer risk in women.

As interest in personalized medicine grows, government contractors are entering the field, the Washington Post reports.

In PLOS this week: Plasmodium knowlesi population genetics, oral microbiome of infants and children, and more.